Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
- PMID: 26843213
- PMCID: PMC4739105
- DOI: 10.1186/s12944-016-0191-x
Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
Erratum in
-
Erratum to: Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.Lipids Health Dis. 2016 Mar 22;15:62. doi: 10.1186/s12944-016-0230-7. Lipids Health Dis. 2016. PMID: 27004696 Free PMC article. No abstract available.
Abstract
Background: The prevalence of chronic kidney disease is rising continuously. Cardiovascular disease is among leading causes of death and premature mortality of patients with chronic kidney disease. Even the earliest stages of chronic kidney disease are associated with higher risk of subsequent coronary heart disease. The aim of this study was to determine markers of increased risk of atherosclerosis in CKD.
Methods: The study group consisted of a total of 80 patients (20 patients with stage I/II CKD, 20 with stage III CKD, 20 stage IV CKD and 20 stage V/dialysis) and 24 healthy volunteers. Levels of proteins (osteoprotegerin, osteopontin, osteocalcin, matrix γ-carboxyglutamic acid protein, fetuin A, MMP-2, MMP-9, TIMP-1, TIMP-2) and biochemical parameters were measured to analyse their influence on atherosclerosis risk in CKD patients. Cardiac echocardiography was performed to assess structural integrity and function, presence of left ventricular hypertrophy and systolic and diastolic function dysfunction.
Results: This study shows that the prevalence of ventricular hypertrophy (95.3 %) and diastolic dysfunction (93.2 %) in CKD patients is high. Also E/E' ratio was significantly higher (13.6 ± 4.4, p = 0.001), tricuspid insufficiency (27.3 in CKD I/II vs. 71.4 in CKD V, p = 0.016), contractile dysfunction (33.3 in CKD I/II vs. 78.9 in CKD V, p = 0.040), mitral valve calcification (0 in CKD I/II vs. 28.6 in CKD V, p = 0.044) and aortic valve calcification (0 in CKD I/II vs. 61.9 in CKD V, p = 0.0008) were significantly more frequent in patients with CKD stage V/dialysis than in other groups. Only MMP-2, MMP-2/TIMP-2 ratio and TIMP-1 differed significantly between groups.
Conclusions: This study shows high prevalence of ventricular hypertrophy and diastolic dysfunction in CKD patients. Contractile dysfunction, mitral and aortic valve calcification in HD patients were significantly more frequent than in patients with other CKD stages. Significantly increased levels of MMP-2, MMP-2/TIMP-2 ratio and lower TIMP-1 suggests that these factors may be involved in the pathogenesis of atherosclerosis in CKD patients.
Similar articles
-
Markers of increased cardiovascular risk in patients with chronic kidney disease.Lipids Health Dis. 2014 Aug 21;13:135. doi: 10.1186/1476-511X-13-135. Lipids Health Dis. 2014. PMID: 25145866 Free PMC article.
-
Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment.Cell Stress Chaperones. 2011 Jan;16(1):97-103. doi: 10.1007/s12192-010-0214-x. Epub 2010 Sep 6. Cell Stress Chaperones. 2011. PMID: 20821177 Free PMC article.
-
Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.Int Urol Nephrol. 2011 Jun;43(2):491-8. doi: 10.1007/s11255-009-9683-1. Epub 2009 Dec 2. Int Urol Nephrol. 2011. PMID: 19953348
-
Aortic Aneurysms, Chronic Kidney Disease and Metalloproteinases.Biomolecules. 2021 Jan 30;11(2):194. doi: 10.3390/biom11020194. Biomolecules. 2021. PMID: 33573220 Free PMC article. Review.
-
Osteopontin, kidney injury molecule-1, and fetuin-A as prognostic markers of end-stage renal disease: A systematic review and meta-analysis.PLoS One. 2025 Apr 9;20(4):e0320804. doi: 10.1371/journal.pone.0320804. eCollection 2025. PLoS One. 2025. PMID: 40202988 Free PMC article.
Cited by
-
Association of Circulating Tissue Inhibitor of Metalloproteinases-1 and Procollagen Type III Aminoterminal Peptide Levels With Incident Heart Failure and Chronic Kidney Disease.J Am Heart Assoc. 2019 Apr 2;8(7):e011426. doi: 10.1161/JAHA.118.011426. J Am Heart Assoc. 2019. PMID: 30890055 Free PMC article.
-
Erratum to: Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.Lipids Health Dis. 2016 Mar 22;15:62. doi: 10.1186/s12944-016-0230-7. Lipids Health Dis. 2016. PMID: 27004696 Free PMC article. No abstract available.
-
Vitamin K Dependent Proteins in Kidney Disease.Int J Mol Sci. 2019 Mar 29;20(7):1571. doi: 10.3390/ijms20071571. Int J Mol Sci. 2019. PMID: 30934817 Free PMC article. Review.
-
Clinical SYNTAX Score - a good predictor for renal artery stenosis in acute myocardial infarction patients: analysis from the REN-ACS trial.Arch Med Sci. 2017 Jun;13(4):837-844. doi: 10.5114/aoms.2016.60374. Epub 2016 Jun 6. Arch Med Sci. 2017. PMID: 28721152 Free PMC article.
-
Beneficial Effects of 6-Month Supplementation with Omega-3 Acids on Selected Inflammatory Markers in Patients with Chronic Kidney Disease Stages 1-3.Biomed Res Int. 2017;2017:1680985. doi: 10.1155/2017/1680985. Epub 2017 Nov 19. Biomed Res Int. 2017. PMID: 29349065 Free PMC article.
References
-
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. doi: 10.1038/kisup.2012.73. - DOI
-
- National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–266. - PubMed
-
- Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–69. doi: 10.1161/01.CIR.0000095676.90936.80. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous